Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder

Young M. Park, Heon-Jeong Lee, Seung G. Kang, Jae Hyuck Cho, Leen Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, and is therefore an antidepressant with unique pharmacological properties. There are some reports that selective serotonin reuptake inhibitors (SSRIs) or mirtazapine can induce adverse effects including restless legs syndrome (RLS) and that bupropion can reverse these adverse effects. Here, we report about a patient with a major depressive disorder who exhibited RLS after being treated with pregabalin and mirtazapine. This adverse effect disappeared after having switched from mirtazapine to bupropion. Bupropion inhibits the reuptake of dopamine and increases dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex. This pharmacological profile can be effective in patients with RLS related to dopamine hypoactivity. However, the limitations of this single case report mean that further investigations with larger samples are needed.

Original languageEnglish
Pages (from-to)313-315
Number of pages3
JournalPsychiatry Investigation
Volume6
Issue number4
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Bupropion
Restless Legs Syndrome
Major Depressive Disorder
Dopamine
Dopamine Uptake Inhibitors
Pharmacology
Nucleus Accumbens
Serotonin Uptake Inhibitors
Prefrontal Cortex
Synaptic Transmission
Antidepressive Agents
Norepinephrine
mirtazapine
Pregabalin

Keywords

  • Bupropion
  • Mirtazapine
  • Pregabalin
  • Restless legs syndrome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder. / Park, Young M.; Lee, Heon-Jeong; Kang, Seung G.; Cho, Jae Hyuck; Kim, Leen.

In: Psychiatry Investigation, Vol. 6, No. 4, 01.12.2009, p. 313-315.

Research output: Contribution to journalArticle

@article{6ee22679cdc24ced9df362074d8fef36,
title = "Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder",
abstract = "Bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, and is therefore an antidepressant with unique pharmacological properties. There are some reports that selective serotonin reuptake inhibitors (SSRIs) or mirtazapine can induce adverse effects including restless legs syndrome (RLS) and that bupropion can reverse these adverse effects. Here, we report about a patient with a major depressive disorder who exhibited RLS after being treated with pregabalin and mirtazapine. This adverse effect disappeared after having switched from mirtazapine to bupropion. Bupropion inhibits the reuptake of dopamine and increases dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex. This pharmacological profile can be effective in patients with RLS related to dopamine hypoactivity. However, the limitations of this single case report mean that further investigations with larger samples are needed.",
keywords = "Bupropion, Mirtazapine, Pregabalin, Restless legs syndrome",
author = "Park, {Young M.} and Heon-Jeong Lee and Kang, {Seung G.} and Cho, {Jae Hyuck} and Leen Kim",
year = "2009",
month = "12",
day = "1",
doi = "10.4306/pi.2009.6.4.313",
language = "English",
volume = "6",
pages = "313--315",
journal = "Psychiatry Investigation",
issn = "1738-3684",
publisher = "Korean Neuropsychiatric Association",
number = "4",

}

TY - JOUR

T1 - Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder

AU - Park, Young M.

AU - Lee, Heon-Jeong

AU - Kang, Seung G.

AU - Cho, Jae Hyuck

AU - Kim, Leen

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, and is therefore an antidepressant with unique pharmacological properties. There are some reports that selective serotonin reuptake inhibitors (SSRIs) or mirtazapine can induce adverse effects including restless legs syndrome (RLS) and that bupropion can reverse these adverse effects. Here, we report about a patient with a major depressive disorder who exhibited RLS after being treated with pregabalin and mirtazapine. This adverse effect disappeared after having switched from mirtazapine to bupropion. Bupropion inhibits the reuptake of dopamine and increases dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex. This pharmacological profile can be effective in patients with RLS related to dopamine hypoactivity. However, the limitations of this single case report mean that further investigations with larger samples are needed.

AB - Bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, and is therefore an antidepressant with unique pharmacological properties. There are some reports that selective serotonin reuptake inhibitors (SSRIs) or mirtazapine can induce adverse effects including restless legs syndrome (RLS) and that bupropion can reverse these adverse effects. Here, we report about a patient with a major depressive disorder who exhibited RLS after being treated with pregabalin and mirtazapine. This adverse effect disappeared after having switched from mirtazapine to bupropion. Bupropion inhibits the reuptake of dopamine and increases dopamine neurotransmission in both the nucleus accumbens and the prefrontal cortex. This pharmacological profile can be effective in patients with RLS related to dopamine hypoactivity. However, the limitations of this single case report mean that further investigations with larger samples are needed.

KW - Bupropion

KW - Mirtazapine

KW - Pregabalin

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=75649127611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649127611&partnerID=8YFLogxK

U2 - 10.4306/pi.2009.6.4.313

DO - 10.4306/pi.2009.6.4.313

M3 - Article

C2 - 20140131

AN - SCOPUS:75649127611

VL - 6

SP - 313

EP - 315

JO - Psychiatry Investigation

JF - Psychiatry Investigation

SN - 1738-3684

IS - 4

ER -